文献速递主动脉疾病

LEOPARD试验中市售腔内移植物的五年结果

Five-year results of the LEOPARD trial of commercially available endografts.
PubMed 文献 · J Vasc Surg · 2023-04-15

LEOPARD试验是一项前瞻性随机多中心研究,在455例肾下腹主动脉瘤患者中比较解剖固定AFX/AFX2移植物与近端固定移植物。5年免于动脉瘤相关并发症的Kaplan-Meier估计值AF组为63.8%,PF组为55.5%(P=0.10),动脉瘤相关死亡率、全因死亡率、破裂、二次干预及I/III型内漏均无差异。结论认为两组在总体动脉瘤相关结局上无临床显著差异。

要点

  • 5年免于动脉瘤相关并发症率AF组63.8% vs PF组55.5%(P=0.10),无统计学显著差异。
  • AF组5年II型内漏率78.8% vs PF组68.4%(P=0.037),AF组较低。
  • AF组开放手术转换0例(0.0%)vs PF组4例(2.0%)。

核心结论

  • LEOPARD研究5年结果显示,随机分配至AFX移植物或市售近端固定移植物的患者在总体动脉瘤相关结局上无临床显著差异。

研究设计与样本

  • 前瞻性、随机、多中心试验,纳入美国56个中心的455例肾下腹主动脉瘤患者,AF组235例,PF组220例。

主要发现

  • 5年免于动脉瘤相关并发症的Kaplan-Meier估计值AF组为63.8%,PF组为55.5%(P=0.10)。
  • 1年和5年免于动脉瘤相关死亡的Kaplan-Meier估计值AF组分别为98.7%和97.0%,PF组分别为99.5%和98.5%。
  • 两组在动脉瘤相关死亡、全因死亡、破裂、二次干预及I型和III型内漏方面无差异。
  • 5年III型内漏率AFX组为1.5%,对照组为0.0%(P=0.11)。
  • 5年II型内漏率AF组为78.8%,PF组为68.4%(P=0.037),AF组较低。

关键数值与推荐

  • 主要终点为免于动脉瘤相关并发症,复合终点包括围手术期死亡(≤30天)、动脉瘤破裂、转换为开放手术、术后内漏、移植物迁移(≥10 mm)、动脉瘤增大(≥5 mm)、移植物分支闭塞及装置或动脉瘤相关再干预。
  • 1年主要终点支持AF队列的非劣效性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The LEOPARD (Looking at EVAR Outcomes by Primary Analysis of Randomized Data) trial is a randomized controlled trial comparing the outcomes of endovascular aneurysm repair (EVAR) using commercially available devices in a real-world population. METHODS: A prospective, randomized, multi-center trial was performed to compare the anatomically fixated (AF) AFX/AFX2 endograft system (Endologix) with endografts with proximal fixation (PF) (Cook Medical Zenith Flex; Gore Excluder; and Medtronic Endurant II) in patients with infrarenal abdominal aortic aneurysms. The primary endpoint was freedom from aneurysm-related complications (ARCs), a composite endpoint consisting of perioperative death (≤30 days), aneurysm rupture, conversion to open surgical repair, postoperative endoleaks, endograft migration (≥10 mm), aneurysm enlargement (≥5 mm), endograft limb occlusion, and device- or aneurysm-related reintervention. RESULTS: The study population was 455 patients enrolled at 56 United States centers: 235 patients were treated with AF devices and 220 with PF devices. The primary endpoint supported noninferiority of the AF cohort at 1 year. The 5-year freedom from ARC Kaplan-Meier estimates were 63.8% for AF patients and 55.5% for PF patients (P = .10). Kaplan-Meier estimates for freedom from aneurysm-related mortality were 98.7% and 97.0% in the AF group and 99.5% and 98.5% in the PF group at 1 and 5 years. There was no difference in aneurysm-related mortality, all-cause mortality, rupture, secondary interventions, and type I and type III endoleak between the two cohorts. The type III endoleak rate at 5 years for the AFX cohort was 1.5% and 0.0% for the comparator cohort (P = .11). There was a lower type II endoleak rate in the AF group at 5 years (78.8% vs 68.4%; P = .037). There were zero open surgical conversions (0.0%) in the AF group and four (2.0%) in the PF group. CONCLUSIONS: The 5-year results from the LEOPARD study demonstrated that there was no clinically significant difference in overall aneurysm-related outcomes between patients randomized to the AFX endograft system or commercially available endografts with proximal fixation.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Kwolek CJ, Ouriel K, Stucky FS, et al. Five-year results of the LEOPARD trial of commercially available endografts. J Vasc Surg. 2023. PMID: 37068528. doi:10.1016/j.jvs.2023.04.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。